14. Medicament comprising at least one compound according to any of claims 1 to 12 and/or a physiologically acceptable salt thereof.

15. Pharmaceutical composition comprising as active ingredient at least one compound according to any of claims 1 to 12 and/or a physiologically acceptable salt thereof together with pharmaceutically tolerable excipients, optionally in combination with one or more further active ingredients.

16. Use of a compound according to any of claims 1 to 12 and/or a physiologically acceptable salt thereof for the preparation of a medicament for the prophylactic or therapeutic treatment and/or monitoring of a disease that is caused, mediated and/or propagated by p70S6K activity.

17. ~~A method~~ Use of a medicament for treating a disease that is caused, mediated and/or propagated by p70S6K activity, wherein said medicament contains at least one compound according to any of claims 1 to 12 and/or a physiologically acceptable salt thereof is administered to a mammal in need of such treatment.

18. ~~The method~~ Use of the medicament according to claim 17, wherein the disease is selected from the group of hyperproliferative disorders, cancer, metastases, tumors, angiogenesis disorders, tumor angiogenesis, benign hyperplasia, hemangioma, glioma, melanoma, Kaposi's sarcoma, prostate diseases related to vasculogenesis or angiogenesis, inflammation, pancreatitis, retinopathy, retinopathy of prematurity, diabetic retinopathy, diabetes, pain, restenosis, psoriasis, eczema, scleroderma and age-related macular degeneration.

19. ~~A method~~ Use of a medicament for inhibiting p70S6K, wherein a system expressing p70S6K is contacted with a medicament containing at least one compound according to any of claims 1 to 12 and/or a physiologically acceptable salt thereof under conditions such that the p70S6K is inhibited.